El grupo Bioingeniería en salud reproductiva del Instituto de Bioingeniería de Cataluña (IBEC) aparece a los medios por su participación en el desarrollo de un dispositivo que ofrezca información metabólica del óvulo antes de criopreservar-lo. … Read more
Oxolife, la startup biotecnológica focalizada en el desarrollo de fármacos para la mejora de la fertilidad femenina, y el Laboratorio de Bioingeniería en Salud Reproductiva del Instituto de Bioingeniería de Cataluña (IBEC), combinarán dos tecnologías pioneras para el estudio y tratamiento de la infertilidad. 
Application Deadline: 15/07/2020
Ref: SR-SO
The Bioengineering in reproductive health group at the Institute for Bioengineering of Catalonia (IBEC) is looking for a Senior Scientist to develop a project in collaboration with the industry.
The project involves investigate the molecular mechanisms affected by specific chemical treatments on endometrial receptivity and on mouse and human embryos in culture. We aim to combine the expertise in microscopy of the lab with embryology tools to understand the morphological and molecular modifications that lead to an increase in endometrial receptivity. An ideal candidate will have experience in the mouse or human embryology field and will know basic tools of molecular biology. The candidate will have a great degree of independence to coordinate the project, competitive salary and funding to outsource several tests (i.e. sequencing, histology etc.).
Our laboratory is a multidisciplinary environment where biologists, biophysicists, clinicians and business developers synergize to create a unique environment shaped by science and entrepreneurship. Due to the high translational component of our research, we have established collaboration contracts with the pharma industry, hospitals and venture capital to bring our technology to the clinics and the market.
In our lab we use bioengineering methods to create 3D environments that support embryonic development outside of the mother uterus. Our systems are accessible to imaging tools which allow us to interrogate the genetics, metabolomics and mechanics of the embryo in a high throughput manner. Using our systems we are capable to (i) improve embryo culture conditions and (ii) diagnose embryos with improved implantation potential.
Application Deadline: 30/06/2020
Ref: LT-SO
The Bioengineering in Reproductive Health Group offers a lab technician position for an experienced cell culture technician to develop a project in collaboration with the industry. The project involves testing the effects of different cell culture supplements on several cell types (e.g. Mesenchymal Stromal Cells, CAR T Cells, etc.)
Our laboratory is a multidisciplinary environment where biologists, biophysicists, clinicians and business developers synergize to create a unique environment shaped by science and entrepreneurship. Due to the high translational component of our research, we have established collaboration contracts with the pharma industry, hospitals and venture capital to bring our technology to the clinics and the market.
In our lab, we develop high-tech projects in the fields of embryology, cell biology and imaging. Our strategy involves the development of new products for the pharmaceutical industry. The current position seeks a motivated cell culture technician with experience in diverse cell culture systems.
Santiago Marco, investigador principal del grupo de Procesamiento de señales e información para sistemas de sensores y Samuel Ojosnegros, responsable de la unidad Bioingeniería en Salud Reproductiva, han sido seleccionados por sus proyectos de investigación en la convocatoria del programa ATTRACT. La convocatoria recibió más de 1200 propuestas de las cuales se seleccionaron 170.El programa ATTRACT es un proyecto pionero de investigación e innovación que forma parte del programa Horizon 2020 financiado por la Unión Europea y respaldado por un consorcio formado por 9 socios. El objetivo principal de este programa es crear un ecosistema de innovación conjunta entre la investigación fundamental y las comunidades industriales para desarrollar tecnologías avanzadas de detección e imagen para usos científicos y comerciales.
Este acuerdo es el primero que se establece en el marco de la nueva iniciativa del instituto, el Open Innovation Lab, que ofrece a empresas e inversores una plataforma para llevar más ágilmente la investigación de vanguardia a los pacientes y al mercado.